| 1 |
34648046 | Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo. | 2022 May |
1 |
| 2 |
34800176 | Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer. | 2022 Jan |
1 |
| 3 |
35467350 | Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. | 2022 Apr 25 |
1 |
| 4 |
35566085 | A Preliminary Study of PSMA Fluorescent Probe for Targeted Fluorescence Imaging of Prostate Cancer. | 2022 Apr 24 |
1 |
| 5 |
33459068 | Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature. | 2021 Jun |
1 |
| 6 |
33637585 | Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study. | 2021 Oct |
2 |
| 7 |
33783213 | Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion. | 2021 Apr 8 |
1 |
| 8 |
34373887 | Synthesis and in vitro preliminary evaluation of prostate-specific membrane antigen targeted upconversion nanoparticles as a first step towards radio/fluorescence-guided surgery of prostate cancer. | 2021 Sep 22 |
1 |
| 9 |
32097010 | Novel β- and γ-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen. | 2020 Mar 26 |
1 |
| 10 |
32140850 | Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients. | 2020 Feb 24 |
2 |
| 11 |
32217372 | Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen. | 2020 Jun |
1 |
| 12 |
32960990 | 18 F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer. | 2020 Dec |
1 |
| 13 |
33302417 | Polypeptide-Based Molecular Platform and Its Docetaxel/Sulfo-Cy5-Containing Conjugate for Targeted Delivery to Prostate Specific Membrane Antigen. | 2020 Dec 8 |
1 |
| 14 |
30485073 | Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer. | 2019 Jan 16 |
1 |
| 15 |
31009566 | Functionally Versatile and Highly Stable Chelator for 111In and 177Lu: Proof-of-Principle Prostate-Specific Membrane Antigen Targeting. | 2019 May 15 |
2 |
| 16 |
31248772 | Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates. | 2019 Aug 15 |
1 |
| 17 |
31502937 | Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer. | 2019 Nov |
2 |
| 18 |
28833667 | Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy. | 2018 Jan 12 |
2 |
| 19 |
29448109 | HDAC1 regulates the stability of glutamate carboxypeptidase II protein by modulating acetylation status of lysine 479 residue. | 2018 Feb 26 |
7 |
| 20 |
29503861 | Synthesis of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform. | 2018 |
1 |
| 21 |
29853810 | Preparation of 68Ga-PSMA-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression during Prostate Cancer Progression. | 2018 |
2 |
| 22 |
27660138 | Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. | 2017 Mar |
1 |
| 23 |
27847991 | Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging. | 2017 Apr |
1 |
| 24 |
28639122 | Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile. | 2017 Dec |
2 |
| 25 |
28950199 | Validation of a [Al18F]PSMA-11 preparation for clinical applications. | 2017 Dec |
2 |
| 26 |
29520394 | Development and Validation of a High-Pressure Liquid Chromatography Method for the Determination of Chemical Purity and Radiochemical Purity of a [68Ga]-Labeled Glu-Urea-Lys(Ahx)-HBED-CC (Positron Emission Tomography) Tracer. | 2017 Oct 31 |
2 |
| 27 |
26404016 | (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. | 2016 Jan |
3 |
| 28 |
27076393 | Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA. | 2016 Jun 15 |
1 |
| 29 |
27248781 | Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics. | 2016 Jul 20 |
3 |
| 30 |
26162799 | PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. | 2015 Nov |
2 |
| 31 |
24464532 | Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. | 2014 May |
1 |
| 32 |
24508213 | Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. | 2014 Apr |
1 |
| 33 |
24939622 | Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes. | 2014 Jul 18 |
3 |
| 34 |
24983957 | Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. | 2014 Jun 30 |
3 |
| 35 |
25518963 | [Ga-68-PSMA PET/CT for prostate cancer]. | 2014 Nov |
1 |
| 36 |
23733925 | 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. | 2013 Aug |
1 |
| 37 |
22207391 | A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). | 2011 Dec |
2 |
| 38 |
18637669 | Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). | 2008 Aug 14 |
2 |
| 39 |
17032155 | Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody. | 2006 Oct |
1 |
| 40 |
15729708 | Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. | 2005 Apr |
1 |
| 41 |
23256224 | 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid | 2004 |
1 |
| 42 |
23256225 | 111In-Labeled (7S)-26-(4-((1-((1-carboxy-5-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)pentyl)amino)-1-oxo-6-(1-((7S)-1,3,7,22-tetracarboxy-5,13,20-trioxo-4,6,12,21-tetraazahexacosan-26-yl)-1H-1,2,3-triazole-4-carboxamido)hexan-2-yl)carbamoyl)-1H-1,2,3-triazol-5-yl)-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic acid | 2004 |
1 |